Literature DB >> 26115360

COMPLETE RESOLUTION OF LARGE RETINAL FOLD AFTER TRANSECTION OF RETROLENTAL MEMBRANE DURING LENS-SPARING VITRECTOMY FOR RETINOPATHY OF PREMATURITY: A 15-YEAR FOLLOW-UP.

Benjamin J Thomas1, Yoshihiro Yonekawa, Michael T Trese.   

Abstract

PURPOSE: To describe the long-term anatomical and visual outcomes of a patient with retinopathy of prematurity characterized by a prominent retinal fold adherent to the posterior lens capsule, treated by lens-sparing vitrectomy with surgical transection of the retrolental membrane. CASE
SUMMARY: A premature infant was born at a gestational age of 25 weeks and birthweight of 636 g. She developed threshold retinopathy of prematurity bilaterally and was subsequently treated with laser ablative therapy. The left eye responded favorably, with regression of neovascularization; however, the right eye progressed to Stage 4A with a prominent retinal fold adherent to the posterior lens capsule. The patient underwent lens-sparing vitrectomy with dissection of the retrolental membrane at postmenstrual age of 44 weeks. At 15-year follow-up, the patient has maintained a best-corrected visual acuity of 20/60 and, of note, demonstrated complete resolution of the previous retinal fold.
CONCLUSION: Surgical treatment for retinopathy of prematurity was considerably advanced by the introduction of lens-sparing vitrectomy techniques; however, cases developing retrolental membranes often persisted with poor visual outcomes, and lensectomy is conventionally performed. However, in select cases of Stage 4A retinopathy of prematurity, careful transection of retrolental membranes during lens-sparing vitrectomy using the appropriate technique may provide very good anatomical and visual outcomes.

Entities:  

Mesh:

Year:  2016        PMID: 26115360     DOI: 10.1097/ICB.0000000000000170

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  1 in total

1.  Successful scleral buckling of late-onset visual decrease in eye with retinal folds.

Authors:  Yuri Nakayama; Satoshi Katagiri; Tadashi Yokoi; Makiko Ui; Sachiko Nishina; Noriyuki Azuma
Journal:  Doc Ophthalmol       Date:  2016-08-23       Impact factor: 2.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.